Nikhil Munshi, MD, on Final Data on Cilta-Cel in Multiple Myeloma From CARTITUDE-1

Video

The associate professor from Dana Farber Cancer Center and Harvard Medical School discussed continued efficacy and safety data presented at the 2023 EHA Meeting.

“The take home message is that CAR T-cells are extremely effective. The toxicity is manageable and so, its utilization in our patients, even in elderly patients, should become an important component of therapeutic management... I do see CAR T-cell probably aspart of a combined immunotherapy approach CAR T-cells and bispecificimmunomodulators are going to become standard of treatment, and most likely curative treatment in myeloma.”

A final analysis of the phase 1b/2 CARTITUDE-1 trial (NCT03548207) of the approved chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti; Janssen) in patients with relapsed/refractory multiple myeloma was presented at the European Hematology Association (EHA) 2023 Congress, held June 8-11, both virtually and in Frankfurt, Germany, by Nikhil Munshi, MD, director, Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center; Kraft Family Chair, director of Multiple Myeloma Immune Effector Cell Therapy, senior physician at Dana-Farber Cancer Institute; and a professor of Medicine at Harvard Medical School.

CGTLive™’s sister site, OncLive™, spoke with Munshi while at EHA to learn more about the updated data and the continued efficacy seen with cilta-cel since its 2022 approval. He also went over the study population and the favorable safety profile observed. Munshi shared his thoughts about the future outlook with CAR T-cell therapy and multiple myeloma, including bringing up the use of CAR T-cell therapy into earlier lines of treatment and combining modes of treatment such as bispecific antibodies with CAR T-cell therapy.

Click here for more coverage of EHA 2023.

REFERENCE
Munshi N, Martin T, Usmani SZ, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. Presented at: EHA 2023 Congress. Abstract S202
Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
© 2024 MJH Life Sciences

All rights reserved.